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small myocardial infarcts were observed in the heart. Treatment with r-RGD-Hiru- 
din,(lmg/kg and 5 q/kg, n=lZ)significantly reduced the area and number of minor myo- 
cardial infarction(pc0.01 conpared with control). CONCLUSIONS: We present a new 
model of minor myocardial infarction in rats in which the small coronary arteries are 
occluded by microthrombi. This model is useful to investigate the pathophysiology and 
treatment of minor myocardial infarction which is ccmmcn in interventional treatment. R- 
RGD-Hirudin may be beneficial in the treatment of minor myocardial infarction induced 
by PTCA. 
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Background The remodeling process IS a major cause of heart failure and deaths after 
myocardial infarction (Ml). Marrow stromal cell (MSCs) was shown to enhance angiogen- 
esis and regenerate cardiomyocytes in rat ischemic heart model. This study is designed 
to test the effectiveness of MSCs implantation to reverse myocardial remodeling. 
Methods Autologous MSCs were induced into a zone made ischemic by coronary artery 
ligation 1 week after Ml via intramyocardial(n=lO) or intracoronary (n=lO) implantation. 
Control rats received medium (intramyocardial, n=lO; intracoronaiy, n=lO). Rats with EF 
~70 % 1 week after Ml were included. Scar area index and the scar thickness is mea- 
sured by computer-assistant planimetry as indices of myccardial remodeling 0 weeks 
after implatation. The diameter of myocytes in the p&infarct zcne were also measured. 
Histology study were done by HE and PTAH stain. 
Results Eight weeks after implantations, serial section of transplanted area showing 
regenerated muscle tissue surrounded by host infarction scar in PTAH-stained heart sec- 
tion. lefl ventricular end-diastolic diameter reduced significantly in MSCs group 
(0.706*0.150 mm vs. 0.968+0.094 mm in control group, p<O.Ol). The scar area index 
also reduced in MSCs group (25.5%*5.2% vs. 45.3%+15.2% in control group, PcO.01) 
and the scar thickness increased in MSCs group (1.45iO.32 mm vs. 0.88i0.29mm in 
control group. P-zO.01). Moreover, the myccytes at the peri-infarct zcne of MSCs group 
were significantly larger than that of control group (diameter:0.033+0.011 mm vs. 
0.021+0.009 mm, P<O.Ol). 
Conclusion Our data indicate that MSCs implantation reversed myocardial remodeling 
and improved scar healing by regeneration of muscular tissue after Ml. 
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Background: Glycoprotein (GP) llbillla inhibitors improve cutccmes when used during 
primary PCI for ST-elevation myocardial infarctton (STEMI), but the risks and benefits of 
GP Ilb/llla inhibitors dunng rescue/early PCI after full-dose fibrinolytic therapy have not 
been well-characterized. 
Methods: We performed a meta-analysis of data from 11 clinical trials evaluating new 
repedusion regimens for STEMI (ASSENT 1,2, and 3, GUSTO Ill and V, TIMI 108 and 
14. In-TIME-2. SPEED, FASTER, and INTEGRITI). Patients (n = 3,342) treated with full- 
dose fibrinolytic therapy who then underwent early PCI within 24 hours were included. 
The risks of moderate/severe bleeding by the GUSTO scale, intracranial hemorrhage 
(ICH). and 30-day mortality were evaluated stratified by the adjunctive use of GP llbillla 
inhibitors within the first 24 hours. 
Results: Patients treated with GP Ilb/llla inhibitors were younger (mean age 57.3 vs. 
58.3 yrs), heavier (mean weight 84.8 vs. 81.6 kg), less commonly female (18.5% vs. 
20.8%), less commonly had an anterior infarct (40.9% vs. 42.4%), and rncre commonly 
had diabetes (17.0% vs. 14.7%). Unadjusted outcomes are listed in the table. 
GP Ilbl No GP Ilb/ Odds 95% Cl P- 
llla llla Ratio Value 
(n = (n = 2304) 
1038) 
Moderate/Severe Bleeding 17.1 11.6 1.71 1.24. 0.001 
(%) 2.36 
ICH (%) 0.48 0.89 0.75 0.26- 0.586 
2.13 
30.Day Mortality (%) 3.7 4.9 0.78 0.54- 0.214 
1.15 
Conclusions: In this post-hoc, non-randomized analysis, the use of GP Ilb/llla inhibitors 
during rescue/early PCI following full-dose fibrinolytic therapy was associated with a 
higher rate of non-ICH bleeding complications. Prospective, randomized clinical trials are 
therefore needed to delineate the risks and benefits of this treatment strategy. 
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Background: Prognosis in acute myocardial infarction (AMI) is mainly determined by 
early repelfusion and restoration of a normal flow in the infarct related artery. However, 
reperfusion therapy for AMI with thrombolysis has been shown to achieve a 50% TIMI-3- 
flow only. Early trials combining thrombolysis and PTCA have failed to show a mortality 
benefit mainly due to encountered bleeding complications. Since the reduced fibrinolytic 
therapy in combination with a platelet glycoprotein llblllla inhibitor (COMBO) has recently 
shown to reduce the rate of AMI related complications, ‘“facilitated” PCI needs new eval- 
uation. 
Methods: Since 12/2000 120 patients with an AMI were randomized in Leipzig, Ger- 
many within 6 hours after symptom onset to either a prehospital COMBO (half dose 
Reteplase + abciximab) with in-hospital conservative therapy (r&8) or a prehospital initi- 
ated COMBO therapy with immediate in-hospital “facilitated’ PCl+stent (n=62). Primary 
endpoints were ST-segment resolution at 90 min., infarct size expressed as area under 
the curve of CK-release and as delayed enhancement MRI. The secondary endpoint was 
a composite of mortality, reAMI, major bleeding and stroke. 
Results: Mean time from symptom onset to arrival of the emergency physlcian was 107+ 
81 min. in COMBO only in comparison to 105+ 127 min. in the facilitated PCI-group 
(p=n.s.). In the facilitated PC&group TIMI-3-flow before intervention was 65% and after 
98%, respectively. 90-min ST-segment resolution was mere complete in the facilitated 
PCI group (772 56% vs. 58+ 47%. p=O.O4). Infarct size measured by CK-release was 
900* 817 in the COMBO only versus 847t 482 pmol/l/h in the facilitated PCI-group 
(~~0.07) and 1 I+ 8% versus 7+ 8% in the delayed enhancement MRI (p=O.16). The sec- 
ondary combined endpoint was similar in both groups without an excess in bleeding com- 
plicatlons in the facilitated group. (14% vs. 13%, p=n.s.). 
Conclusion: The prehospital combined thrombolytic therapy with abciximab is feasible 
and these results show that “facilitated” PCl+stent results in a an improved tissue perfu- 
sion as shown by the ST-segment resolution, which leads to a trend of smaller infarcts 
without excess in encountered complications. 
12:24 p.m. 
1025MP-165 A Prospective Multicenter International Randomized 
Trial Comparing Infarct Artery Stenting Alone With 
Infarct Artery Stenting Plus Abcixlmab in Acute 
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Background: Previous randomized studies comparing stent plus abclximab with stent 
alone in pts with acute myocardial infarction (AMI) have produced conflicting results 
about the benefit of abciximab as adjunctive treatment to infarct artery stenting. How- 
ever, these studies enrolled mainly low-risk patients, or were done with first generation 
stents. 
Methods: To determine the impact of abciximab therapy as adjunct to infarct artery 
stenting in AMI, 400 pts. without any restriction based on age or clinical status on presen- 
tation, were randomized at 4 sites to primary stenting alone (n =200) or stenting plus 
abciximab (n=200). The stent used was the Carbostant (Sorin. Italy). There were no 
angiographic exclusion criteria except for a reference Infarct artery diameter < 2.5 mm. 
The primary endpoint of the study was the 1 -month composite incidence of death, reinf- 
arction. repeat target vessel revascularization (TVR), and stroke (MACCE). 
Results: Mean age 63.7 f 12.7; ) 70 yrs 36%; female 23%; diabetes 17%; anterior AMI 
43%; cardiogenic shock 9%; not-low-risk patients (TIMI criteria) 66%; median time from 
